Clinical Trials Browser

Phase 2 × Cholangiocarcinoma × S 1 (combination) × Clear all

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Phase 2 Enrolling by invitation

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06664021 2025-01-10

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT01963325 2018-02-05

S-1 in Combination With Abraxane in Treating Cholangiocarcinoma

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma